Vivendy Therapeutics Ltd. (Vivendy) is a privately held bio-pharmaceutical start up company, engaged in offering clinical research and contract research services. Currently, the company is involved in developing an enzyme replacement therapy (ERT) for morbus morquio (Mucopolysaccharidosis (MPS IVA), a rare lysosomal storage disease (LSD). Its main research focus is to identify a recombinant protein which can improve enzyme activity, there by enhancing the efficacy of the therapy in MPS IVA. Vivendy Therapeutics holds a world wide licence on IP containing a pharmaceutical composition, a fusion protein and own IP on enhancing enzyme activity. The company is headquartered in Basel, Switzerland.